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Objective:Well-differentiated papillary mesothelioma is an uncommon subtype of mesotheli-
oma with a frequently indolent course, although it occasionally manifests in a more aggressive
form. To establish a treatment strategy for this rare disease, we report the clinical characteristics
and outcomes of 15 patients with well-differentiated papillary mesothelioma.
Methods: All pathologically diagnosed well-differentiated papillary mesothelioma cases were
reviewed between 1998 and 2012.
Results: Of the 15 cases, 8 and 7 presented with single and multiple lesions, respectively. All
cases with single lesions were asymptomatic, while 4 out of the 7 cases with multiple lesions
were symptomatic. After tumor excision, none of the eight single-lesion cases experienced
tumor recurrence. Among the other seven cases with multiple lesions, only one patient with dis-
seminated lesions died due to disease burden. Five patients with multiple lesions received cis-
platin-based intravenous or intraperitoneal chemotherapy, with a mix of complete (n ¼ 2) and
partial (n ¼ 2) responses observed. Of particular note, one patient receiving cisplatin and peme-
trexed combination chemotherapy experienced complete tumor resolution without any serious
toxicity.
Conclusions:We recommend different treatment strategies based on the disease status. If the
tumor is completely resectable, an excisional biopsy seems to be sufficient. If complete resec-
tion is unavailable for the asymptomatic patient with a localized tumor extent, close follow-up is
an appropriate option. When the tumor is extensive or accompanied by symptoms, chemother-
apy should be strongly considered.
Key words: well-differentiated papillary mesothelioma – peritoneum – chemotherapy – cisplatin –
pemetrexed – therapeutic strategy
INTRODUCTION
Malignant mesothelioma is a mesothelial cell originating
tumor, which is strongly associated with asbestos exposure
and carries a very poor prognosis (1). Well-differentiated
papillary mesothelioma (WDPM) is a distinct subtype of
mesothelioma that demonstrates a papillary architecture
arising in the peritoneum of women of reproductive age
without a history of asbestos exposure (2,3). WDPM is usually
incidentally detected during surgery for other indications and
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is known to behave in a benign or indolent fashion in many
cases (2,4–6). In our experience, WDPM demonstrates a wide
spectrum of clinical behavior, ranging from indolent course to
disseminated disease resulting in death. Because of its rarity,
only a few series have been reported, mostly emphasizing the
pathologic features of WDPM, and the clinical features and
treatment outcomes are poorly deﬁned (2–6). Some WDPM
patients underwent various local and systemic treatments,
while other patients were only regularly followed without any
treatment (3,5,6). Therefore, an extensive review of the clinic-
al features with a relatively large sample size is warranted.
In this study, we describe the clinical features and treatment
outcomes of 15 cases of peritoneal WDPM. Based on our pre-
vious experience, we established prognostic factors for clinic-
al outcomes in this disease. We also analyzed detailed
chemotherapy regimens and their responses to ﬁnd a promis-
ing treatment option.
MATERIALS ANDMETHODS
Between 1998 and 2012, a total of 15 cases of newly diag-
nosed WDPM at two institutions in Korea were retrospectively
reviewed. The inclusion criteria were: (i) pathologically con-
ﬁrmed diagnosis of WDPM; (ii) complete clinical information
which was deﬁned by patient demographics, primary tumor
site, disease extent, treatment record and survival follow-up.
Follow-up data included tumor recurrence with local or
distant metastasis, and details of vital status, including
whether the patient is alive without disease, alive with
diseases, dead of other cause or dead as a result of WDPM or
WDPM treatment. Treatment response was evaluated by
response evaluation criteria in solid tumors.
RESULTS
PATIENT CHARACTERISTICS
The clinical characteristics of the 15 cases included in the ana-
lysis are provided in Table 1. Nine patients (60%) were
women with a median age of 53 years (range 23–76 years). In
terms of multiplicity of lesions, eight and seven patients pre-
sented with single and multiple lesions, respectively. Among
the 11 asymptomatic cases, 9 were incidentally diagnosed
during abdominal surgery, 1 was diagnosed during a health
check-up and 1 with Von-Hippel–Landau disease was diag-
nosed during routine screening for renal cell carcinoma. The
other four patients were initially symptomatic, of which two
presented with abdominal pain and two had abdominal disten-
sion. Most asymptomatic cases demonstrated only a single
lesion (8 out of 11), while all symptomatic cases were diag-
nosed with multiple lesions. Four out of seven patients with
multiple lesions had tumors disseminating throughout the
peritoneum, while the tumors of three patients arose from
focal peritoneal lesions. Information on tumor size was avail-
able in 11 cases, and this ranged from 0.4 to 7.1 cm (median
1.2 cm). A detailed history of asbestos exposure was available
in 12 cases and no patients worked in occupations with a high
likelihood of asbestos exposure.
TREATMENT MODALITIES AND SURVIVAL OUTCOME
Detailed treatment and follow-up information is summarized
in Table 1. The overall follow-up period ranged from 6 to 146
months. For the eight patients with a single WDPM lesion
(Cases 1–8), complete tumor excision was performed, includ-
ing excisional biopsy (n ¼ 7) and right salpingo-oophorectomy
(n¼1). Adjuvant treatment was performed for four of these
patients with 5-ﬂuorouracil (5-FU)-based chemotherapy. None
of the patients experienced tumor recurrence, and six patients
are alive while two died of other causes (one recurred rectal
cancer and the other an uncertain cause).
For the seven cases presenting with multiple lesions, one
patient with seven lesions on the peritoneum (Case 9) under-
went excisional biopsies for two of the seven lesions, and
another patient with numerous omental lesions (Case 10) did
not receive any surgery, except for initial laparoscopic biopsy.
Both of these patients received no adjuvant therapy for their
residual tumors, and are still alive with disease. The other ﬁve
patients with multiple lesions (Cases 11–15) underwent
chemotherapy at some time in their disease course. Among
the four evaluable patients, two complete responses (CRs) and
two partial responses (PRs) were observed. One patient (Case
11) received aggressive surgical resection with total abdomin-
al hysterectomy, bilateral salpingo-oophorectomy, bilateral
pelvic lymph node dissection, infracolic omentectomy and
multiple peritoneal biopsies. After three cycles of adjuvant
paclitaxel and cisplatin chemotherapy, she obtained a PR
and is alive with disease after 4 years. One patient (Case 12)
had synchronous WDPM with B-viral hepatocellular carcin-
oma and he received 12 cycles of 5-FU and cisplatin com-
bination chemotherapy. A CR was conﬁrmed by positron
emission tomography–computed tomography (PET–CT), and
he is alive without WDPM recurrence after 8 years. One
patient who presented with low abdominal pain (Case 13)
received two cycles of adriamycin and cisplatin combination
chemotherapy. Although the response data were not identiﬁed,
she is alive after .12 years. One patient with massive ascites
and a pleural effusion (Case 14) received three cycles of intra-
peritoneal (IP) chemotherapy. A PR was initially obtained, but
he died of tumor progression 9 years after the initial diagnosis.
Of particular interest, one patient was initially diagnosed
with signiﬁcant ascites and a pleural effusion attributed to a
disseminated tumor burden (Case 12). A surgical biopsy of
the omentum was performed during laparoscopy. Biopsy
tissue contained part of the tumor, which was characterized by
papillae consisting of stout ﬁbrovascular cores covered by a
single layer of relatively uniform bland-looking cuboidal
mesothelial cells (Fig. 1A and B). Immunohistochemically,
tumor cells were positive for D2–40 and calretinin (Fig. 1C
and D). She received pemetrexed and cisplatin combination
chemotherapy. After eight courses of chemotherapy, the
Jpn J Clin Oncol 2013;43(10) 997
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Table 1. Clinical features of 15 WDPM patients
Case Age
(year)
Sex Presentation Tumor number and
extension
Largest tumor
size (cm)
Surgical
treatment
Residual
tumor
Chemotherapy Response Follow-up
1 23 F Incidental for RCC
screening
Single 3.5 Excisional
biopsy
No No N/A NED 20 months
2 62 F Incidental ﬁnding Single 1.2 Excisional
biopsy
No Adjuvant FOLFOX4a, 12 cycles N/A NED 48 months
3 66 F Incidental ﬁnding Single 0.4 Excisional
biopsy
No No N/A DOC 6 months
4 53 M Incidental ﬁnding Single 0.5 Excisional
biopsy
No No N/A NED 22 months
5 45 M Incidental ﬁnding Single INA Excisional
biopsy
No Adjuvant 5-FU-based
chemotherapy
N/A NED 146 months
6 59 M Incidental ﬁnding Single 1.2 Excisional
biopsy
No Adjuvant 5-FU-based
chemotherapy
N/A DOC 47 months (recurred
rectal cancer)
7 62 M Incidental ﬁnding Single INA Excisional
biopsy
No Adjuvant oral 5-FU N/A NED 12 months
8 43 F Incidental ﬁnding Single 6 RSO No No N/A NED 49 months
9 47 F Incidental ﬁnding Multiple, localized 0.5 Excisional
biopsy
Yes No N/A AWD 42 months
10 52 F Lower abdominal pain Multiple, localized 1.2 No Yes No N/A AWD 62 months
11 64 F Incidental ﬁnding Multiple, localized 1.0 TAH-BSO Yes Paclitaxel/cisplatinb, 3 cycles PR AWD 48 months
12 58 M Incidental ﬁnding Multiple, disseminated 0.5 No Yes 5-FU/cisplatinc, 12 cycles CR NED 96 months
13 36 F Lower abdominal pain Multiple, disseminated 7.1 No Yes Adriamycin/cisplatind, 2 cycles INA AWD 145 months
14 76 M Ascites and pleural
effusion
Multiple, disseminated 3.7 No Yes Cisplatin+mytomycine,
3 times (IP)
PR DOD 110 months
15 49 F Ascites and pleural
effusion
Multiple, disseminated 0.5 No Yes Pemetrexed/cisplatinf, 8 cycles CR NED 18 months
RCC, renal cell carcinoma; RSO, right salpingo-oopherectomy; TAH-BSO, total abdominal hysterectomy with bilateral salpingo-oopherectomy; CCRT, combined chemoradiation therapy; IP, intraperitoneal;
N/A, not applicable; PR, partial response; CR, complete response; INA, information not available; NED, no evidence of disease; DOC, dead of other cause; AWD, alive with disease; DOD, dead of disease;
WDPM, well-differentiated papillary mesothelioma.
aOxaliplatin 85 mg/m2 Day 1, leucovorin 200 mg/m2 Days 1–2, 5-FU 400 mg/m2 Days 1–2, 5-FU 600 mg/m2 Days 1–2.
bPaclitaxel 175 mg/m2 Day 1, cisplatin: 70 mg/m2 Day 2.
c5-FU 1000 mg/m2 Days 1–5, cisplatin 80 mg/m2 Day 2.
dAdriamycin 45 mg/m2 Day 1, cisplatin 70 mg/m2 Day 1.
eFirst: cisplatin 30 mg, second: cisplatin 50 mg and mytomycin 10 mg, third: cisplatin 50 mg.
fPemetrexed 500 mg/m2 Day 1, cisplatin 75 mg/m2 Day 1.
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pleural effusion and ascites resolved (Fig. 2A and B) and PET–
CT imaging showed no signs of abnormal ﬂuorodeoxyglucose
uptake (Fig. 2C and D). In addition, no serious toxicity was
demonstrated, and she completed the chemotherapy without
dose reduction or treatment delay. She is alive without tumor
recurrence 12 months after treatment completion.
Figure 2. (A) Computed tomography (CT) images at the time of initial diagnosis show ascites (red arrow) and a pleural effusion (blue arrow). (B) After eight
cycles of pemetrexed and cisplatin chemotherapy, ascites and pleural effusion resolved (red and blue arrows). (C) Positron emission tomography–computed
tomography (PET–CT) image of initial diagnosis showed an abnormally increased ﬂuorodeoxyglucose (FDG) uptake of omentum (green arrow). (D) After eight
cycles of treatment, FDG uptake was resolved (green arrow).
Figure 1. Histopathologic ﬁndings of well-differentiated papillary mesothelioma (WDPM) from the representative patient (Case 12). (A) Hematoxylin and eosin
staining, 40. (B) Hematoxylin and eosin staining, 200. (C) Calretinin immunostaining, 100. (D) D2–40 immunostaining, 100.
Jpn J Clin Oncol 2013;43(10) 999
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DISCUSSION
In contrast to the malignant mesothelioma, WDPM is much
rarer and has a relatively indolent course and carries a good
prognosis (3,6). In addition, female cases are more frequently
reported and the majority of patients are between 20 and 50
years (2,3,6,7). WDPM is primarily seen in the peritoneum,
but it is sometimes detected in the pleura, pericardium, tunica
vaginalis and epididymis (2,4,6–8). Though the association
with asbestos is rarely reported, pleural WDPM is often asso-
ciated with asbestos exposure (4–6). Diagnosis is usually
made incidentally during surgery for other indications (6,7).
However, it presents with symptoms of abdominal pain,
abdominal distension, menorrhagia, haematospermia and
dyspnea (2–9). Although many reports show WDPM with an
indolent clinical course, some cases describe more aggressive
features resulting in tumor-related deaths (4,5,10–13).
Because of its rarity, no standardized treatment has been
established. In previous studies, some patients received no
additional treatment but remained in stable condition and
showed little or no disease progression (2–6). A debulking
surgery was performed for some patients (3,6,7,14). Medical
treatment was also sometimes performed, including intraven-
ous (IV) or IP chemotherapy, radiation therapy, immunother-
apy, sclerosing therapy and combinations thereof, but the
beneﬁt of these treatments has not been clearly demonstrated
(3,5,7,14). In particular, one author reported 26 patients with
WDPM who underwent complete resection without adjuvant
therapy for WDPM, and only one patient experienced recur-
rence, which was surgically curable (6). Thus, some authors
suggest simply removing bulky masses when present and fol-
lowing the patient with close observation (2,3,6). However,
some patients who experience disease progression and deaths
attributed to disease burden have been reported (4,5,10–13).
Therefore, it is worthwhile to consider WDPM as a disease
with malignant potential, which requires active treatment. In
addition, further work is needed to determine how to identify
the high-risk patients who need aggressive treatment. In this
study, we describe the various clinical courses of WDPM
patients and suggest a treatment strategy based on identiﬁable
risk factors. To our knowledge, this is the ﬁrst study which
depicts the clinical characteristics and suggests a treatment
strategy for this rare disease. Considering its rarity, 15 cases of
WDPM is likely to be helpful in outlining clinical outcomes.
Only a few studies have previously reported chemotherapy
treatment for WDPM (2,4,5,7,9,11,14–16). Most of the cases
described here presented with peritoneal involvement, and
various kinds of chemotherapy were administered as shown in
Table 2 (2,4,7,9,11,15,16). Seven cases were treated with IV
chemotherapy, four cases with IP chemotherapy and two cases
with combined systemic and local treatment. Among those
cases, two patients received complete tumor excision followed
by either IP hyperthermic chemoperfusion of mitomycin C
with 5-FU (case I) or cisplatin with doxorubicin (Case K)
(11,16). The former patient was alive without recurrence 6
months later, while the latter patient experienced recurrence
within 15 months. The direct response to chemotherapy could
be assessed in only one case (Case L) (9). She presented with
extensively disseminated peritoneal nodules accompanied by
ascites and pleural effusion. An aggressive debulking surgery
was performed and residual ascites and pleural effusion
totally resolved after additional IP, intrapleural and IV carbo-
platin administration. She is alive without disease after 4
years. Another symptomatic patient (Case M) was also treated
with aggressive surgery followed by extensive IV and IP
chemotherapy (7). Although the detailed response to chemo-
therapy was not described, she is alive with disease after .20
years. Therefore, optimal cytoreductive surgery and combined
chemotherapy seem to be an appropriate treatment strategy
when a poor prognosis is predicted.
In our study, we identiﬁed some interesting trends in patient
outcomes. Tumor size does not seem to have a clear effect on
symptoms or prognosis of WDPM, especially when the tumor
can be excised. Two patients with a large mass did not experi-
ence any symptoms at the time of diagnosis, or recurrences
after tumor removal (Cases 1 and 8). Patients with multiple
lesions, however, were more likely to be symptomatic than
those with a single lesion. The eight patients with single
lesions (Cases 1–8) did not experience any symptoms at the
time of diagnosis. However, four out of seven patients with
multiple disseminated tumors presented with disease-related
symptoms (Cases 10 and 13–15). In particular, three out of
those four symptomatic patients showed massive tumor in-
volvement throughout the peritoneum. This ﬁnding is consist-
ent with previous reports, in which most symptomatic patients
had multiple lesions (2,4,6,7,9). In addition, the prognosis of
WDPM is likely to be correlated with disease extent. Most
WDPM cases were discovered incidentally prior to developing
symptoms according to the previous studies (6). However,
among the seven patients from previous studies who died due
to WDPM, all of four evaluable patients showed multiple
lesions at diagnosis and presented with symptoms at diagnosis
or shortly after diagnosis (4,5,10–13). This ﬁnding is compat-
ible with our study. Among our patients only one died of
disease progression (Case 11). He had extensive disease with
a large volume of ascites at diagnosis. These ﬁndings suggest
that disseminated tumor extent causes symptoms and results
in a poor prognosis. Therefore, these factors should be care-
fully considered when deciding on a treatment strategy for
WDPM.
Based on our study, we could evaluate potential therapeutic
strategies for this rare disease. When WDPM tumors were
completely excised, recurrence was rare even without adjuvant
therapy (Cases 1–8). If complete excision is not available,
platinum-based chemotherapy seems to be effective. All of
our four evaluable patients who received cisplatin demon-
strated a favorable tumor response in our study (Cases 8, 9, 11
and 12). Furthermore, two patients who underwent cisplatin-
based IV chemotherapy showed complete resolution. These
ﬁndings are consistent with previous studies, in which surgical
resection followed by chemotherapy demonstrated favorable
survival outcomes (2,4,7,9,11,15,16). However, the efﬁcacy
1000 Treatment for peritoneal WDPM
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Table 2. Clinical feature of 13 WDPM of peritoneum patients who received chemotherapy reported in the literature
Case Age
(year)
Sex Presentation Tumor number and
extension
Surgery Residual
tumor
Chemotherapy: regimen (type) Response Other therapy Follow-up
A 46 M Constipation INA Done INA Cisplatin and doxorubicin (IV) INA No NED, 3 years
B 38 M Abdominal pain Multiple,
disseminated
Done INA Cisplatin and doxorubicin (IV) INA No DOD, 3 years
C 32 F Ascites INA Done INA Ranpirnase (IV) INA No AWD, unknown
period
D 11 F Abdominal pain Multiple,
disseminated
RSO and omentectomy Yes Cisplatin/cyclophosphamide
(IV, as neoadjuvant therapy)
INA Luprolide AWD, 11 months
E 69 F Incidental ﬁnding during
TAH-BSO
Multiple, localized TAH-BSO INA INA (IV) INA No Alive, 2 years
F 25 F Ascites and left pelvic
mass
INA TAH-BSO and
omentectomy
INA INA (IV) INA Radiotherapy Death, uncertain
cause, 7 years
G 31 F Incidental ﬁnding during
left oophorectomy
Multiple, localized Left oophorectomy INA INA (IV) INA Radiotherapy Death, uncertain
cause, 2 years
H 48 F Ascites Multiple,
disseminated
No Yes Thiotepa (IP) INA Radiotherapy AWD, 4 years
I 55 F Incidental ﬁnding during
LAR
Multiple,
disseminated
LAR, omentectomy and
peritonectomy
No Mitomycin/ﬂuorouracil (IPHC) N/A No NED, 6 months
J 48 F INA INA Cytoreductive surgery Yes Cisplatin/mytomycin (IPHC) INA No DOD, 13 months
K 47 F INA INA Cytoreductive surgery No Cisplatin/doxorubicin (IPHC) N/A No AWD, 15 months
(Recurrence)
L 56 F Ascites and right pleural
effusion
Multiple,
disseminated
TAH-BSO and
omentectomy
Yes Carboplatin (IP, intrapleural
and IV)
CR No NED, 4 years
M 36 F Abdominal pain Multiple,
disseminated
TAH-BSO Yes Sixth lines of chemotherapy
(IV+ IP)
INA Tamoxifen and
megace
AWD, 24 years
LAR, low anterior resection; IV, intravenous; IPHC, intraperitoneal hyperthermic chemoperfusion.
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of radical surgery which exceeds simple tumor excision is de-
batable. One patient still had a residual tumor even after
undergoing radical debulking surgery before chemotherapy
(Case 8). In contrast, two patients with a complete response to
chemotherapy did not receive surgery (Cases 9 and 12).
If the tumor is completely resectable, regardless of whether
it presents as a single or multiple lesions, complete excision is
an acceptable treatment. In these cases, adjuvant therapy is
generally not necessary and regular follow-up seems to be suf-
ﬁcient, considering the rarity of recurrence after complete re-
section (6). If the tumor is multifocal and unresectable,
chemotherapy should be considered. If the patient is asymp-
tomatic and disease extent is localized, then close follow-up
might be sufﬁcient considering the indolent nature of WDPM
and the potential complications of aggressive treatment.
However, chemotherapy should be more strongly considered
if the tumor is extensive or accompanied by symptoms such
as abdominal pain or distension, because these ﬁndings
appear to be associated with a poor prognosis. Cytoreductive
surgery and adjuvant chemotherapy might be an option, but
radical surgery exceeding simple tumor resection may not be
beneﬁcial.
To determine the most effective chemotherapy regimen for
WDPM, we can apply some information known about malig-
nant mesothelioma, which can be considered as a malignant
counterpart to WDPM. Platinum-based combination regimens
demonstrated superior outcomes compared with single-agent
regimens or non-platinum-based combinations (17,18).
Currently, the cisplatin and pemetrexed doublet therapy has
been established as the effective ﬁrst-line chemotherapy for
advanced malignant mesothelioma (1,18–20). The combin-
ation of cisplatin and pemetrexed showed far greater activity
than cisplatin alone (19). Though peritoneal mesothelioma is
rarer than mesothelioma of the pleura, one subgroup analysis
indicated acceptable activity and safety for peritoneal meso-
thelioma (21). However, cisplatin and pemetrexed combin-
ation has not been previously used for peritoneal WDPM. One
WDPM patient with pleural involvement was treated with
three courses of neoadjuvant cisplatin and pemetrexed com-
bination followed by extrapleural pneumonectomy, but the re-
sponse to chemotherapy was not described in the study (14).
Cisplatin-based chemotherapy appeared to be effective among
the cases described here, and one patient in particular was suc-
cessfully treated with eight courses of cisplatin and peme-
trexed regimen without any signiﬁcant toxicity. Although she
was diagnosed with massive ascites and pleural effusion sec-
ondary to WDPM, she experienced complete disease remis-
sion via chemotherapy alone (Case 12). Therefore, cisplatin
and pemetrexed doublet therapy may be a promising treatment
option for extensive or symptomatic WDPM.
It is obvious that there is a room for debate on the optimal
treatment of WDPM. Although WDPM usually shows low
malignant potential and an indolent clinical course, more ag-
gressive therapies are needed for patients at higher risk of ma-
lignant transformation. We have extensively reviewed
previous literature and analyzed clinical courses according to
the patient characteristics. We recommend different treatment
strategies based on the disease status. In addition, pemetrexed
and cisplatin combination could be a promising therapeutic
option for WDPM. To our knowledge, this is the ﬁrst study
which extensively reviewed the clinical aspects of WDPM.
We also suggest risk-based treatment strategies with newer
chemotherapeutic agents. Further studies with a larger sample
size will help elucidate the most effective and safe therapeutic
strategies.
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